Hexarelin vs ipamorelin

Hexarelin and ipamorelin stimulate growth hormone through the ghrelin-receptor system, but their research differs. Small human hexarelin experiments measured brief cardiac changes and a smaller growth hormone (GH) response during repeated exposure. Ipamorelin has animal selectivity data, a human infusion study and a postoperative trial with uncertain clinical benefit. These findings do not establish which provides better muscle growth or long-term safety.

Research reviewed October 15, 2026. Educational information only.

A shared receptor leaves different experiments to explain

Hexarelin is a synthetic six-residue growth hormone secretagogue; ipamorelin has five residues. Secretagogue means a substance that stimulates release of a hormone. Both belong to the ghrelin-receptor system rather than being the growth hormone protein itself. That shared classification does not establish equal receptor actions in every tissue, equal exposure or equal clinical effects.

The most useful contrast comes from what investigators actually measured. Hexarelin’s selected human work includes immediate heart pumping and how the GH response changes during repeated exposure. Ipamorelin’s original characterization emphasized hormone selectivity in animals, followed by a human concentration study and a placebo-controlled trial after bowel surgery. Those experiments cannot be collapsed into a single ranking of potency or health benefit.

The main differences

A brief heart-pumping change with hexarelin

Bisi and colleagues studied seven male volunteers after intravenous hexarelin or recombinant human GH. Imaging measured the fraction of blood expelled from the left ventricle with each beat, called left ventricular ejection fraction. With hexarelin this fraction rose from 64.0 ± 1.5% to 70.7 ± 3.0% (P<0.03). The abstract supplies these variability figures without defining their statistic. The change appeared by fifteen minutes, peaked at thirty and lasted up to sixty minutes.

Direct GH produced a similar total growth-hormone exposure over the sampling period but did not produce the same cardiac response. Cortisol increased with hexarelin, while mean blood pressure and heart rate were not established as changed. This pattern suggests that the acute heart response cannot be explained simply by more circulating GH. The small experiment did not establish fewer cardiovascular events, better exercise capacity or longer survival.

Ipamorelin was not the comparator in this study. Its absence matters: the result supplies evidence about hexarelin versus direct GH and baseline measurements, without demonstrating a cardiac advantage over ipamorelin.

The GH response to hexarelin became smaller over time

Rahim and Shalet followed twelve healthy older adults during sixteen weeks of repeated subcutaneous hexarelin exposure. They summarized the GH response to testing using the area under its concentration curve, which measures the hormone response accumulated over the sampling period. This response fell from 19.1 ± 2.4 at baseline to 13.1 ± 2.3 at week one, 12.3 ± 2.4 at week four and 10.5 ± 1.8 μg·h/L at week sixteen (means ± standard errors). The decreases at weeks four and sixteen were established relative to baseline (P<0.05 and P<0.01).

Four weeks after exposure ended, the response rose to 19.4 ± 3.7 μg·h/L, above the week-sixteen value (P<0.05) and not established as different from baseline. The attenuation was therefore partial and reversible in that sample. This measured change in responsiveness is different from how quickly hexarelin disappears from blood.

The human ipamorelin infusion study did not conduct a matching sixteen-week comparison. Its single-episode GH response cannot establish that ipamorelin avoids attenuation with long-term exposure. Neither study measured a shared clinical outcome such as sustained strength or recovery from injury.

Ipamorelin’s selectivity, exposure and postoperative findings

The original ipamorelin paper studied rat pituitary cells, rats and conscious pigs. In pigs, ipamorelin released GH, while ACTH and cortisol responses were not established as higher than those with growth hormone-releasing hormone (GHRH); GHRP-2 and GHRP-6 increased these stress-related hormones in the tested conditions. ACTH is a pituitary signal to the adrenal glands, which release cortisol. This comparison describes relative hormone selectivity in pigs and does not directly compare hexarelin and ipamorelin in humans.

Gobburu and colleagues then measured circulating ipamorelin and GH after short intravenous infusions in healthy men. The estimated peptide terminal half-life was about two hours, and GH peaked around 0.67 hours. Eight men participated at each of five exposure levels; the abstract does not state a total unique participant count. No muscle or functional recovery endpoint was tested.

In the bowel-resection trial, 117 adults were enrolled and 114 entered the main analysis populations. Median time to tolerate a standardized solid meal was 25.3 hours with intravenous ipamorelin and 32.6 with placebo. The earlier numerical time did not establish efficacy (P=0.15), with secondary analyses also uncertain. This clinical outcome differs from hexarelin’s acute cardiac and repeated-hormone measurements.

Hormonal selectivity cannot establish a safety ranking

The hexarelin volunteer experiment found a cortisol increase, and the repeated-exposure study documented a changing GH response. These findings are relevant physiology, but their small samples and short or limited follow-up cannot characterize long-term cardiovascular, metabolic or other clinical harms. A brief rise in ejection fraction is not a safety outcome proving protection of the heart.

Ipamorelin’s pig data cannot supply the missing human comparison. In the postoperative trial, at least one adverse event after treatment began was reported in 87.5% of ipamorelin recipients and 94.8% of placebo recipients, a setting with many causes of complications. FDA’s review also describes two deaths among ipamorelin recipients with postoperative complications; causation was unclear. The agency flags potential immune reactions from aggregation or peptide impurities and limited information for some injectable routes.

The available literature therefore cannot establish that ipamorelin is safer because it was more selective in one animal hormone panel, or that hexarelin is safer because it briefly changed a pumping measurement. Safety requires an adverse-event assessment in the actual preparation, route, population and duration being considered.

What remains unresolved for a clinical comparison

The studies establish that these peptides can stimulate GH and that their measured effects vary with biological system and repeated exposure. Hexarelin has a small acute human cardiac observation and evidence of partial loss of GH responsiveness during sixteen weeks. Ipamorelin has a human exposure estimate and a postoperative clinical comparison that did not establish benefit. None of these findings determines which improves healthy-adult muscle growth, sleep, injury recovery or lifespan.

The hexarelin profile develops its cardiac and repeated-response experiments, while the ipamorelin profile distinguishes the animal and human results. For a different pituitary receptor input, read ipamorelin vs sermorelin.

Frequently asked questions

Profiles and related reading

References

1. Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G, Arvat E, Boghen MF, Deghenghi R, Muccioli G, Ong H, Ghigo E. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. Journal of endocrinological investigation. 1999;22(4):266–272. doi:10.1007/BF03343555. PMID:10342360.

   In seven men, intravenous hexarelin briefly increased the fraction of blood pumped out of the left ventricle with each beat, from 64.0% to 70.7%. Direct growth hormone did not produce the same cardiac change despite similar total growth-hormone exposure over the sampling period. Cortisol rose with hexarelin.

2. Rahim A, Shalet SM. Does desensitization to hexarelin occur?. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1998;8 Suppl B:141–143. doi:10.1016/s1096-6374(98)80039-7. PMID:10990150.

   In twelve healthy older adults, the GH response to a hexarelin challenge became smaller during 16 weeks of subcutaneous exposure. Four weeks after treatment ended, it increased again to a value not established as different from baseline.

3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998;139(5):552–561. doi:10.1530/eje.0.1390552. PMID:9849822.

   Ipamorelin released growth hormone in cells, rats and pigs. In pigs, responses of ACTH, a pituitary signal to the adrenal glands, and the stress hormone cortisol were not established as higher than responses to growth hormone-releasing hormone (GHRH). GHRP-2 and GHRP-6 raised those hormones under the tested conditions.

4. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. 1999;16(9):1412–1416. doi:10.1023/a:1018955126402. PMID:10496658.

   Healthy men received short intravenous ipamorelin infusions. The peptide’s estimated terminal half-life was about two hours; released growth hormone peaked around 0.67 hours. The abstract gives eight men at each level without a unique total.

5. Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. 2014;29(12):1527–1534. doi:10.1007/s00384-014-2030-8. PMID:25331030.

   After bowel resection, median time to tolerate a solid meal was 25.3 hours with intravenous ipamorelin and 32.6 hours with placebo. This favorable numerical difference did not establish benefit (P=0.15); 114 of 117 enrolled people formed the main analysis populations.

6. U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee. Ipamorelin-related bulk drug substances briefing document.

   The agency reviews the uncertain postoperative efficacy comparison and safety events, including two deaths among ipamorelin recipients with postoperative complications. Drug causation was unclear; the report does not establish safety for other injectable routes.

7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed October 15, 2026.

   FDA identifies immune-reaction and peptide-quality concerns for CJC-1295 and ipamorelin acetate. It also notes increased heart rate and systemic vasodilation with CJC-1295 and serious events in intravenous ipamorelin research, without establishing causation for every event.

8. Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. European journal of endocrinology. 1996;134(6):716–719. doi:10.1530/eje.0.1340716. PMID:8766941.

   The paper identifies the amidated six-residue hexarelin sequence used in seven short prepubertal children. GH responses became smaller during prolonged intranasal exposure while growth speed increased; these observations concern a different population and route from the older-adult study.

9. Benso A, Prodam F, Lucatello B, Gramaglia E, Riganti F, Schneider H, van der Lely AJ, Muccioli G, Ghigo E, Broglio F. d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans. Neuropeptides. 2007;41(1):45–49. doi:10.1016/j.npep.2006.10.001. PMID:17112585.

   In six healthy volunteers, intravenous ghrelin or hexarelin increased GH, prolactin, ACTH and cortisol. A proposed ghrelin-receptor antagonist did not block these responses, questioning its usefulness as an antagonist in human experiments.

10. Rahim A, O’Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. The Journal of clinical endocrinology and metabolism. 1998;83(5):1644–1649. doi:10.1210/jcem.83.5.4812. PMID:9589671.

    This companion report gives the same baseline and week-sixteen growth-hormone response areas as the later report. Its concentration-times-hour units clarify the accumulated hormone measurement; it is not a separate replication.